News

Zydus Lifesciences will hold a meeting of the Board of Directors of the Company on 19 May 2026.

Zydus Lifesciences announced that the USFDA conducted GMP surveillance Inspection for the company`s Unit 9 facility located at Zydus Biotech Park, Changodar, Ahmedabad. The inspection was conducted from 27 April to 5 May 2026. The inspection closed with seven observations. There were no data integrity related observations. The company will closely work with the USFDA to address the observations expeditiously.

Zydus Lifesciences has received the Establishment Inspection Report (EIR) and approval letter from the USFDA for the Pre-Approval Inspection (PAI) conducted at SEZ oncology injectable manufacturing site in SEZ1, Ahmedabad, in relation to the new isolator injectable line. The inspection was conducted from 4th to 13th November, 2025

Zydus Lifesciences announced that ESG Risk Assessments and Insights (ESGRAIL), a SEBI registered ESG Rating Provider has assigned overall ESG rating of 68 (last year 66) to the Company.

Zydus Lifesciences has received final approval from the United States Food and Drug Administration (USFDA) for Dapagliflozin Tablets, 5 mg and 10 mg (USRLD: Farxiga� Tablets, 5 mg and 10 mg). Dapagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus. With this approval, Zydus is eligible for 180 days of shared generic drug exclusivity for Dapagliflozin Tablets, 5 mg and 10 mg. Dapagliflozin tablets will be manufactured at the group`s formulation manufacturing facility at SEZ, Ahmedabad. Dapagliflozin tablets had annual sales of USD 10.2bn in the United States (IQVIA MAT February 2026).